Scholars Central

Research articlePublished 2012

The Glycoprotein Growth Factor Progranulin Promotes Carcinogenesis and has Potential Value in Anti-cancer Therapy

Authors: Yonghua Zhang, Andrew Bateman

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Progranulin (PGRN) is a secreted glycoprotein growth factor with tumorigenic roles in a variety of tumors including, among others, breast, ovarian, prostate, bladder, and liver cancer. In some patients, for example with breast, ovarian or liver cancers, high PGRN expression in tumors correlated with a worse outcome. Studies using cell lines and animal models provide evidence that PGRN promotes tumor cell proliferation, migration and survival, and induces drug resistance. Increasing or decreasing PGRN production enhances or inhibits respectively the growth of PGRN-sensitive tumors in vivo. PGRN activity is associated with p44/42 mitogen-activated protein kinase as well as phosphatidylinositol 3-kinases signaling pathways. In addition, PGRN may stimulate the formation of the tumor stroma. As an extracellular regulator of tumorgenesis, PGRN is a potential therapeutic target and biomarker of prognosis in the treatment of various cancers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Carcinogenesis & Mutagenesis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Carcinogenesis & Mutagenesis
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Yonghua Zhang”
  • BylineArticles whose byline prints “Andrew Bateman”